Feature Article

Personalized Medicine in Psoriasis: Patient Stratification Is Key Step Forward

By

Although truly personalized medicine is not yet feasible in psoriasis treatment, a stratified approach to selection of therapies may offer some of the benefits of personalized medicine.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Psoriasis

Ixekizumab Effective for Psoriasis Regardless of Psoriatic Arthritis Status

By April 17, 2018

The investigators concluded that ixekizumab therapy is a safe and effective treatment for the improvement of efficacy and health measures in patients with plaque psoriasis during a 12-week period, regardless of a patient's psoriatic arthritis status at baseline.

Psoriasis

Psoriasis Treatment Ixekizumab Safe for Cardiovascular Health

By April 17, 2018

Biologic therapies for psoriasis may have an impact on cardiovascular parameters, potentially resulting in the occurrence of major adverse cardiovascular events.

Psoriasis

Differentiating Responders to Systemic Therapies From Nonresponders With Psoriasis

By April 12, 2018

Treatment decisions are difficult to make in psoriasis patients, given the paucity of objective tools for evaluation of response to treatment.

Psoriasis

Shortness of Breath in Psoriasis May Be Linked to Reduced FEV1

By April 11, 2018

Psoriasis is a chronic inflammatory systemic disease associated with several comorbid conditions, including chronic obstructive pulmonary disease and asthma.

Psoriasis

Psoriasis Disease Perceptions Differ Between Patients, Dermatologists

By April 09, 2018

Further communication between the patient and provider is needed to better understand the impact of disease severity and treatment.

Psoriasis

Guselkumab More Effective Than Adalimumab for Reduction of Psoriasis Symptoms

By April 09, 2018

Investigators analyzed data from the first year of VOYAGE 1, an ongoing, phase 3, double-blind, controlled trial of patients with moderate to severe psoriasis.

Psoriasis

Brodalumab Effective for Reduction of Itch Associated With Psoriasis

By April 05, 2018

In AMAGINE-1/2/3, brodalumab improved PSI total and itch scores from week 2 through 12, compared with placebo (both P <.001).

Psoriasis

Screening Tool Helps Identify Psoriasis Patients In Need of Rheumatology Consult

By April 04, 2018

Diagnosis of PsA was made by rheumatologists using CASPAR criteria, and univariate associations between the items and PsA diagnosis were analyzed.

Psoriasis

Biologic Therapies Generally Safe in Psoriasis with Comorbid Cirrhosis

By March 28, 2018

The investigators sought to examine adverse events and outcome parameters in a group of patients with psoriasis who were treated with biologics and had received a diagnosis of cirrhosis.

Psoriasis

Ilumya Approved for Moderate-to-Severe Plaque Psoriasis

By March 27, 2018

The FDA approval of Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program.

Sign up for Newsletters